Ivabradine may reduce HF Readmissions

11:27 am Health Care, Medicine

Ivabradine added to standard heart failure therapy reduced HF readmissions by a third in patients with systolic heart failure compared with patients on standard treatment, according to a post hoc analysis of data from the SHIFT trial, reports Jeffery S. Borer, MD, of the State University of New York Downstate Medical Center in Brooklyn and colleagues in European Heart Journal.

The trial randomized 3,268 patients to ivabradine at a maximum dose of 7.5 mg twice daily or to matched placebo on top of beta-blocker therapy. All patients had symptomatic heart failure and left ventricular function of less than 35%.

The trial randomized 3,268 patients to ivabradine at a maximum dose of 7.5 mg twice daily or to matched placebo on top of beta-blocker therapy. All patients had symptomatic heart failure and left ventricular function of less than 35%.

Comments are closed.